XmAb18087

BIOLOGICAL2 trials

Sponsors

Xencor, Inc.

Conditions

Gastrointestinal NeoplasmMerkel Cell CarcinomaNeuroendocrine TumorSmall Cell Lung Cancer

Phase 1

A Study of XmAb®18087 in Subjects With NET and GIST

CompletedNCT03411915

Xencor, Inc.Gastrointestinal Neoplasm, Neuroendocrine Tumor

Start: 2018-01-22End: 2021-10-26Updated: 2022-05-10

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

TerminatedNCT04590781

Xencor, Inc.Merkel Cell Carcinoma, Small Cell Lung Cancer

Start: 2021-05-10End: 2022-03-24Updated: 2023-04-20